13669-70-0

13669-70-0 structure

Name: Nefopam
Chemical Name: 3-Methyl-7-phenyl-6-oxa-3-azabicyclo[6.4.0]dodeca-8,10,12-triene
CAS Number: 13669-70-0
Molecular Formula: C₁₇H₁₉NO
Molecular Weight: 253.339
Catalog: API Antipyretic analgesics Analgesic
Create Date: 2018-02-13 08:00:00
Modify Date: 2024-01-09 18:57:28
Nefopam (Fenazoxine) is an orally active, non-opioid and non-steroidal centrally acting analgesic agent. Nefopam blocks voltage-sensitive sodium channels (IC50=27 µM) and modulates glutamatergic transmission in rodents. Nefopam can be used in studies of neuropathic pain, anticonvulsant, as well as the prevention of postoperative shivering and hiccups[1][2][3].

Name	3-Methyl-7-phenyl-6-oxa-3-azabicyclo[6.4.0]dodeca-8,10,12-triene
Synonyms	5-Methyl-1-phenyl-3,4,5,6-tetrahydro-1H-2,5-benzoxazocine Sinalgico EINECS 237-148-2 5-methyl-1-phenyl-3,4,5,6-tetrahydro-1H-2,5-benzoxazocine hydrochloride 5-Methyl-1-phenyl-3,4,5,6-tetrahydro-1H-benzo[f][1,4]oxazocine Ajan 1H-2,5-Benzoxazocine, 3,4,5,6-tetrahydro-5-methyl-1-phenyl- 3,4,5,6-Tetrahydro-5-methyl-1-phenyl-1H-2,5-benzoxazocine Nefopam MFCD00056181 Acupan

Description	Nefopam (Fenazoxine) is an orally active, non-opioid and non-steroidal centrally acting analgesic agent. Nefopam blocks voltage-sensitive sodium channels (IC50=27 µM) and modulates glutamatergic transmission in rodents. Nefopam can be used in studies of neuropathic pain, anticonvulsant, as well as the prevention of postoperative shivering and hiccups[1][2][3].
Related Catalog	Signaling Pathways >> Others >> Others Research Areas >> Neurological Disease
In Vitro	Nefopam (0.1-100 µM; 15 min) inhibits the uptake of 22Na in a concentration-dependent manner in SK-N-SH cells[1]. Cell Viability Assay[1] Cell Line: SK-N-SH cells Concentration: 0.1-100 µM Incubation Time: 15 min (preincubate) Result: Inhibited the uptake of 22Na with an IC50 value of 27 µM.
In Vivo	Nefopam (0-10 mg/kg; i.v.; single) protects mice against electroshock induced seizures[1].Nefopam (10, 30, 60 mg/kg; i.p.; single) shows a dose-dependent attenuation of mechanical allodynia and decreased neurokinin-1 receptor concentration in vincristine-induced peripheral neuropathy model[2]. Animal Model: Adult male NMRI mice (25-30 g; 6 to7-week-old; electroshock-induced seizures model)[1] Dosage: 0-10 mg/kg Administration: Intravenous injection; single Result: Produced dose-dependent protection against maximal electroshock seizures in mice with an ED50 of 3.8 (2.9-5.1) mg/kg. Animal Model: Adult male mice (10-week-old; 25-30 g; vincristine-induced peripheral neuropathy model)[2]. Dosage: 10, 30, 60 mg/kg Administration: Intraperitoneal injection; single Result: Significantly decreased the percentage of NK1 receptors in the spinal cord at dosage of 60 mg/kg. Showed a sustained increase in paw withdrawal threshold against mechanical stimuli.

Density	1.1±0.1 g/cm3
Boiling Point	369.5±37.0 °C at 760 mmHg
Molecular Formula	C₁₇H₁₉NO
Molecular Weight	253.339
Flash Point	109.0±28.8 °C
Exact Mass	253.146667
PSA	12.47000
LogP	3.44
Vapour Pressure	0.0±0.8 mmHg at 25°C
Index of Refraction	1.564
Storage condition	2-8°C

CHEMICAL IDENTIFICATION

RTECS NUMBER :: DM4210000

CHEMICAL NAME :: 1H-2,5-Benzoxazocine, 3,4,5,6,7-tetrahydro-5-methyl-1-phenyl-

CAS REGISTRY NUMBER :: 13669-70-0

LAST UPDATED :: 199703

DATA ITEMS CITED :: 4

MOLECULAR FORMULA :: C17-H19-N-O

MOLECULAR WEIGHT :: 253.37

WISWESSER LINE NOTATION :: T68 HN KO&TJ H1 LR

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 15 mg/kg

TOXIC EFFECTS :: Behavioral - changes in motor activity (specific assay) Cardiac - change in rate

REFERENCE :: BMJOAE British Medical Journal. (British Medical Assoc., BMA House, Tavistock Sq., London WC1H 9JR, UK) V.1- 1857- Volume(issue)/page/year: 283,1508,1981

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 17 mg/kg

TOXIC EFFECTS :: Behavioral - hallucinations, distorted perceptions Behavioral - excitement Cardiac - pulse rate increase, without fall in BP

REFERENCE :: BMJOAE British Medical Journal. (British Medical Assoc., BMA House, Tavistock Sq., London WC1H 9JR, UK) V.1- 1857- Volume(issue)/page/year: 283,1508,1981

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 180 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: USXXAM United States Patent Document. (U.S. Patent Office, Box 9, Washington, DC 20231) Volume(issue)/page/year: #4198424

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 50 mg/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - mydriasis (pupillary dilation)

REFERENCE :: DDEVD6 Drug Development and Evaluation. (Gustav Fischer Verlag, Postfach 720143, D-7000 Stuttgart 70, Fed. Rep. Ger.) V.1- 1977- Volume(issue)/page/year: 3,10,1979

HS Code	2933990090

23327-57-3

~98%

13669-70-0

Literature: ARAKIS LTD. Patent: WO2005/56539 A2, 2005 ; Location in patent: Page/Page column 3 ;

17494-19-8

13669-70-0

Literature: Australian Journal of Chemistry, , vol. 35, # 11 p. 2307 - 2314

18409-76-2

13669-70-0

Literature: Australian Journal of Chemistry, , vol. 35, # 11 p. 2307 - 2314

84940-28-3

13669-70-0

Literature: Australian Journal of Chemistry, , vol. 35, # 11 p. 2307 - 2314

Precursor 3
23327-57-3 18409-76-2 84940-28-3
DownStream 1
865-50-9

HS Code	2933990090
Summary	2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

13669-70-0	1346747-15-6
23327-57-3	46868-19-3
66091-32-5	1346603-50-6
108941-80-6	1346603-30-2
2747915-60-0	2747914-61-8